AzTrials
AzTrials

Advanced Malignant Solid NeoplasmPhase 1NCT03784677

A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors

A Phase 1 study testing TRPV6 Calcium Channel Inhibitor SOR-C13 in people with Advanced Malignant Solid Neoplasm and Refractory Malignant Solid Neoplasm, run by M.D. Anderson Cancer Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This phase I trial studies the side effects and best dose of SOR-C13 in treating patients with solid tumors that have spread to other places in the body (advanced) and does not respond to treatment. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
TRPV6 Calcium Channel Inhibitor SOR-C13
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
11 participants
Where
1 siteUnited States
Study dates
29 Jul 2019to 20 Jun 2023
Phase
Phase 1

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • To be eligible for this trial, patients must meet all of the following eligibility criteria.
  • Subjects with a histologic diagnosis of solid tumor cancers of epithelial origin (metastatic epithelial ovarian, pancreatic and prostate cancers are preferred since these tumor types have TRPV6 overexpression).
  • Subjects with advanced refractory cancer for which standard curative or palliative measures do not exist or are no longer effective. There is no limitation on the number or types of prior therapy.
  • Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST1.1).
  • Men or women aged ≥ 18 years.
  • Women of child-bearing potential (who are not postmenopausal for at least one year or are not surgically sterile) and men must agree to use adequate contraception (e.g., hormonal, barrier device, or abstinence) prior to study entry, for the duration of study participation, and for 30 days after the last dose the study agents.
Show all 18Show fewer
  • Patients must have an ECOG performance status of 0 to 1.
  • Patients must have adequate organ functions as defined below:
  • Neutrophils ≥ 1,500 /L
  • Platelets ≥ 100,000 /L
  • Total bilirubin ≤ 1.5 x ULN (upper limit of normal) (except patients with Gilbert's syndrome, who must have a total bilirubin ≤ 3.0 mg/dL)
  • ALT ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases persist
  • Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 45 mL/minute by the Cockcroft-Gault method
  • Albumin ≥ 3.0 g/dL (≥30 g/L)
  • INR (international normalized ratio) ≤1.4
  • Patients should be able to read and fully understand the requirements of the trial, be willing to comply with all trial visits and assessments, and be willing and able to sign an IRB-approved written informed consent document.
  • Subjects must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have a significant active concurrent medical illness precluding protocol treatment.
  • Patients agree to provide archival tissue block or 10 formalin-fixed paraffin-embedded (FFPE) slides paraffin for use in pharmacodynamics correlative studies.

Who cannot join

  • Patients who meet any of the following criteria will be not eligible for the study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring intravenous antibiotics, symptomatic congestive heart failure (NYHA Class III or IV), or history of myocardial infarction, unstable angina, stroke or transient ischemic attack within 6 months prior to study enrollment.
  • History of clinically significant allergic reactions to the study drugs or their analogs, or any component of the products.
  • Any treatment specific for systemic tumor control within 3 weeks prior to the initiation of the study drugs; or within 2 weeks if cytotoxic agents were given weekly (within 6 weeks for nitrosoureas or mitomycin C), or within 5 half-lives for targeted agents with half-lives and pharmacodynamic effects lasting less than 4 days, or failure to recover from toxic effects of any therapy prior to the study drug treatment.
  • Patients who have not recovered from major surgical procedure, or significant traumatic injury (i.e., still need additional medical care for these issues).
  • History of any of the following cardiovascular events or conditions within the past 6 months prior to enrolment: myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, New York Heart Association Class ≥ II chronic heart failure, significant arrhythmia*; QTcF interval >430 msec or use of drugs that prolong the QT interval at screening; family history of long QT syndrome.
Show all 21Show fewer
  • Significant arrhythmias are defined as symptoms of syncope or severe palpitations (palpitations requiring referral to cardiac monitoring), or ECG findings of supraventricular tachycardia (including atrial fibrillation or atrial flutter) or ventricular tachycardia (including ventricular fibrillation) or ventricular ectopy (ventricular premature depolarization)
  • Clinically significant and uncontrolled major medical condition(s) that places the subject at an unacceptably high risk for toxicities. These include, but are not limited to: active infections, symptomatic pulmonary disease, inadequate pulmonary function, seizure disorder, or psychiatric illness.
  • Current use of more than one antihypertensive medication.
  • For patients receiving antihypertensive medication: systolic blood pressure <120 mm Hg and/or diastolic blood pressure <70 mm Hg at screening.
  • Major surgical procedure within 4 weeks prior to enrolment.
  • Lactating or pregnant female.
  • Females of childbearing potential and males not using adequate birth control.
  • Current treatment or treatment within 4 weeks of screening with bisphosphonates.
  • Hypocalcemia at screening.
  • History of acute pancreatitis within 6 months prior to screening.
  • Known hypoparathyroidism, pseudohypoparathyroidism, or vitamin D deficiency, or clinical evidence of other conditions known to associated with hypocalcemia, including hypoalbuminemia, hyperphosphatemia, hypomagnesemia.
  • Current treatment or treatment within 4 weeks of screening with drugs known to reduce serum calcium levels, including: bisphosphonates, antiepileptic drugs, cinacalcet, macrolide antibiotics (such as erythromycin, azithromycin), large doses of corticosteroids (>20 mg/day of prednisone or equivalent), or any IV use of corticosteroids. In addition, long-term use (defined as ongoing use for ≥4 weeks) of corticosteroids within 8 weeks of screening is prohibited.
  • Symptomatic and uncontrolled metastasis to the central nervous system or leptomeningeal or lymphangitic carcinomatosis.
  • Grade 2 or higher peripheral neuropathy.
  • Human immunodeficiency virus requiring HAART treatment due to unknown drug-drug interactions or known active hepatitis B or C.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • M D Anderson Cancer Center

    Houston, Texas, 77030

Other trials in United States

About this study

This phase I trial studies the side effects and best dose of SOR-C13 in treating patients with solid tumors that have spread to other places in the body (advanced) and does not respond to treatment. Drugs used in chemotherapy, such as SOR-C13, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Read the detailed description

PRIMARY OBJECTIVES:

  1. To define the maximum tolerated doses (MTD) of TRPV6 calcium channel inhibitor SOR-C13 (SOR-C13) in subjects with advanced solid tumor cancers of epithelial origin.

II. To define the safety profiles of the treatment.

SECONDARY OBJECTIVES:

  1. To evaluate clinical response signals to the treatment. II. To assess predictive biomarkers (baseline molecular mutation status) and/or resistant pathways by comparing molecular signatures at baseline versus at time of relapse in patients who have achieved objective responses.

OUTLINE: This is a dose-escalation study.

Patients receive TRPV6 calcium channel inhibitor SOR-C13 intravenously (IV) over 2 hours on days 1, 2, 8, 9, 15, 16, 22, and 23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Being tested
TRPV6 Calcium Channel Inhibitor SOR-C13
Medical subject headings
Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TRPV6 Calcium Channel Inhibitor SOR-C13Drug

    Also called SOR-C13

    Given IV

Study groups in NCT03784677
Study groupRoleWhat they receive
Treatment (TRPV6 calcium channel inhibitor SOR-C13)ExperimentalPatients receive TRPV6 calcium channel inhibitor SOR-C13 IV over 2 hours on days 1, 2, 8, 9, 15, 16, 22, and 23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Receives: Drug: TRPV6 Calcium Channel Inhibitor SOR-C13

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of adverse events and serious adverse events

    Will assess clinical symptoms and laboratory values, evaluate vital signs and perform physical exams, with a special attention to treatment- related fatigue, gastrointestinal (GI) symptoms, cardiovascular events, myelosuppression, and neurotoxicity.

    Measured: Up to 30 days after last dose

  2. Incidence of >= grade 2 adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Measured: Up to 30 days after last dose

  3. Dose-limiting toxicities

    Measured: Up to 28 days

  4. Withdrawals from the study due to treatment-related adverse events will be documented

    Measured: Up to 30 days after last dose

  5. Change of the treatment regimen such as dose delay and dose reduction over time by dose level due to treatment-related adverse events

    Measured: Up to 30 days after last dose

Secondary outcomes (3)

  1. Objective responses

    Defined as complete response(CR)s and partial response (PR).

    Measured: Up to 6 months

  2. Clinical benefit

    Defined as stable disease (SD)/CR/PR according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Measured: Up to 6 months

  3. Predictive biomarkers

    Fisher exact test is used to associate potential biomarkers with SD >= 6 months/CR/PR. Next generation sequencing for targeted exome panel and NanoString arrays are used to reveal potential biomarkers of acquired resistance.

    Measured: Up to 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Dec 2018
  2. Study start29 Jul 2019
  3. Primary completion20 Jun 2023
  4. Study completion20 Jun 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
11 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03784677
Sponsor's protocol ID
2018-0680
Other IDs
NCI-2018-02835, 2018-0680
Status last verified
Nov 2023
First submitted
18 Dec 2018
Last updated
18 Nov 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in